Results 201 to 210 of about 306,917 (239)
Some of the next articles are maybe not open access.
The pathogenesis of diabetic nephropathy
Nature Clinical Practice Endocrinology & Metabolism, 2008Between 20% and 40% of patients with diabetes ultimately develop diabetic nephropathy, which in the US is the most common cause of end-stage renal disease requiring dialysis. Diabetic nephropathy has several distinct phases of development and multiple mechanisms contribute to the development of the disease and its outcomes.
Suma, Dronavalli +2 more
openaire +2 more sources
Diabetes and nephropathy is not always equal to diabetic nephropathy
The British Journal of Diabetes & Vascular Disease, 2013In a busy diabetes clinic, it is always easy for the diabetologist to equate nephropathy and diabetes to “diabetic nephropathy”. Certain clinical clues should arouse suspicion of non-diabetic renal disease as this may have important implications in patient management.
Krishnan Swaminathan +3 more
openaire +1 more source
Losartan in diabetic nephropathy
Expert Review of Cardiovascular Therapy, 2004Diabetic nephropathy has become the single most important cause of end-stage renal disease in the USA, Europe and Japan. The earliest marker of incipient diabetic nephropathy is the transition of normoalbuminuria to microalbuminuria at an albumin excretion rate of 20 microg/min.
Norberto, Perico +2 more
openaire +2 more sources
Diabetic Nephropathy: An Overview
2019Diabetic nephropathy (DN) is one of the most feared diabetic chronic microvascular complications and the major cause of end-stage renal disease (ESRD). The classical presentation of DN is characterized by hyperfiltration and albuminuria in the early phases which is then followed by a progressive renal function decline.
Sagoo, Manpreet K., Gnudi, Luigi
openaire +3 more sources
Experimental and Clinical Endocrinology & Diabetes, 2023
Ludwig, Merker +3 more
openaire +2 more sources
Ludwig, Merker +3 more
openaire +2 more sources
SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
Pharmaceutics, 2023Vita Dolžan
exaly

